Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release US FDA Accepts Wockhardt s New Drug Application for Breakthrough Antibiotic Zaynich .
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 19.8 pts more than Nifty Smallcap 250 and 20.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The US FDA has accepted Wockhardt's New Drug Application (NDA) for Zaynich, the company's breakthrough antibiotic. FDA acceptance means the application is complete enough for a substantive review, bringing the drug one step closer to potential US market approval. Zaynich has been developed as a treatment for serious drug-resistant bacterial infections, an area with high unmet medical need. No specific timeline for the FDA decision or projected revenue impact has been disclosed in this filing.
Positive for shareholders as it advances Wockhardt's pipeline toward a potentially lucrative US market launch, though this is regulatory acceptance, not final approval, so commercial upside remains contingent on the FDA's eventual decision.